iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Patten Group Inc.

Patten Group Inc. cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 26.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,029 shares of the financial services provider’s stock after selling 721 shares during the period. Patten Group Inc.’s holdings in iShares Biotechnology ETF were worth $268,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. US Bancorp DE boosted its stake in iShares Biotechnology ETF by 2.8% during the 3rd quarter. US Bancorp DE now owns 14,028 shares of the financial services provider’s stock valued at $2,042,000 after purchasing an additional 378 shares during the period. Farther Finance Advisors LLC boosted its stake in iShares Biotechnology ETF by 64.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 5,770 shares of the financial services provider’s stock valued at $840,000 after purchasing an additional 2,264 shares during the period. Chicago Partners Investment Group LLC boosted its stake in iShares Biotechnology ETF by 45.8% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,689 shares of the financial services provider’s stock valued at $524,000 after purchasing an additional 1,159 shares during the period. Clarity Capital Partners LLC acquired a new position in iShares Biotechnology ETF during the 3rd quarter valued at about $206,000. Finally, James J. Burns & Company LLC boosted its stake in iShares Biotechnology ETF by 20.4% during the 3rd quarter. James J. Burns & Company LLC now owns 2,051 shares of the financial services provider’s stock valued at $298,000 after purchasing an additional 347 shares during the period. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Up 0.1 %

iShares Biotechnology ETF stock opened at $134.36 on Wednesday. The firm has a 50-day moving average price of $135.92 and a two-hundred day moving average price of $140.53. The firm has a market capitalization of $6.35 billion, a price-to-earnings ratio of 24.52 and a beta of 0.84. iShares Biotechnology ETF has a 52-week low of $123.60 and a 52-week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.